Access the full text.
Sign up today, get DeepDyve free for 14 days.
(1976)
In Drug Design, vol
C. Hansch (1981)
The physicochemical approach to drug design and discovery (QSAR)Drug Development Research, 1
S. Prasanna, E. Manivannan, S. Chaturvedi (2005)
QSAR studies on structurally similar 2-(4-methanesulfonylphenyl)pyran-4-ones as selective COX-2 inhibitors: a Hansch approach.Bioorganic & medicinal chemistry letters, 15 2
P. Beswick, S. Bingham, C. Bountra, Terry Brown, K. Browning, I. Campbell, I. Chessell, N. Clayton, S. Collins, J. Corfield, S. Guntrip, C. Haslam, P. Lambeth, F. Lucas, N. Mathews, Graham Murkit, A. Naylor, N. Pegg, Elizabeth Pickup, Hazel Player, H. Price, Alexander Stevens, S. Stratton, Joanne Wiseman (2004)
Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors.Bioorganic & medicinal chemistry letters, 14 21
A. Nallini, K. Saraboji, M. Ponnuswamy (2004)
A study of aromatic hydrogen bonds of peptides with aromatic amino acid side-chains.Indian journal of biochemistry & biophysics, 41 4
A. Naylor (2005)
Identification of 2,3‐Diaryl‐pyrazolo[1,5‐b]pyridazines as Potent and Selective Cyclooxygenase‐2 Inhibitors.ChemInform, 36
P. Prasit, Zhen Wang, C. Brideau, Chi-Chung Chan, S. Charleson, W. Cromlish, D. Ethier, J. Evans, Anthony Ford-Hutchinson, J. Gauthier, R. Gordon, J. Guay, M. Gresser, S. Kargman, Brian Kennedy, Y. Leblanc, S. Léger, J. Mancini, Gary O'Neill, M. Ouellet, M. Percival, H. Perrier, D. Riendeau, Ian Rodger, P. Tagari, M. Thérien, P. Vickers, E. Wong, Lijing Xu, R. Young, R. Zamboni, Susan Boyce, N. Rupniak, Michael Forrest, D. Visco, D. Patrick (1999)
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.Bioorganic & medicinal chemistry letters, 9 13
S. Prasanna, E. Manivannan, S. Chaturvedi (2005)
QSAR analyses of conformationally restricted 1,5-diaryl pyrazoles as selective COX-2 inhibitors: application of connection table representation of ligands.Bioorganic & medicinal chemistry letters, 15 8
D. Hoekman (1996)
Exploring QSAR Fundamentals and Applications in Chemistry and Biology, Volume 1. Hydrophobic, Electronic and Steric Constants, Volume 2 J. Am. Chem. Soc. 1995, 117, 9782Journal of the American Chemical Society, 118
Brian Golden, Steven Abramson (1999)
Selective cyclooxygenase-2 inhibitors.Rheumatic diseases clinics of North America, 25 2
(1979)
Substitution constants for correlation analysis in chemistry and biology
A. Bekhit, Tarek Abdel-Aziem (2004)
Design, synthesis and biological evaluation of some pyrazole derivatives as anti-inflammatory-antimicrobial agents.Bioorganic & medicinal chemistry, 12 8
H. Ulbrich, B. Fiebich, G. Dannhardt (2002)
Cyclooxygenase-1/2 (COX-1/COX-2) and 5-lipoxygenase (5-LOX) inhibitors of the 6,7-diaryl-2,3-1H-dihydropyrrolizine type.European journal of medicinal chemistry, 37 12
Kushol Gupta, Carl Kaub, Kristen Carey, Eduard Casillas, B. Selinsky, P. Loll (2004)
Manipulation of kinetic profiles in 2-aryl propionic acid cyclooxygenase inhibitors.Bioorganic & medicinal chemistry letters, 14 3
A. Verloop, W. Hoogenstraaten, J. Tipker (1976)
Development and Application of New Steric Substituent Parameters in Drug Design
S. Prasanna, E. Manivannan, S. Chaturvedi (2004)
QSAR Analysis of 2,3‐Diaryl Benzopyrans/Pyrans as Selective COX‐2 Inhibitors Based on Semiempirical AM1 CalculationsQsar & Combinatorial Science, 23
S. Prasanna, E. Manivannan, S. Chaturvedi (2004)
Quantitative structure-activity relationship analysis of a series of 2,3-diaryl benzopyran analogues as novel selective cyclooxygenase-2 inhibitors.Bioorganic & medicinal chemistry letters, 14 15
J. Talley, David Brown, J. Carter, M. Graneto, C. Koboldt, J. Masferrer, W. Perkins, R. Rogers, A. Shaffer, Yan Zhang, B. Zweifel, K. Seibert (2000)
4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2.Journal of medicinal chemistry, 43 5
I. Bjarnason (1999)
COX-2 inhibitorsThe Lancet, 353
S. Prasarina, E. Manivannan, S. Chaturvedi (2004)
QSAR analysis of 2,2-dimethyl-4,5-diaryl-furan-3(2H)-ones as selective cyclooxygenase-2 inhibitorsIndian Journal of Chemistry Section B-organic Chemistry Including Medicinal Chemistry, 43
E. Manivannan, S. Prasanna, S. Chaturvedi (2004)
Rationalization of physico-chemical properties of 5, 6-diarylthiazolo [3,2-b]-1, 2, 4-triazoles towards cyclooxygenase-2 (COX-2) inhibition: a QSAR approach.Indian journal of biochemistry & biophysics, 41 4
N. Pommery, T. Taverne, A. Telliez, L. Goossens, C. Charlier, J. Pommery, J. Goossens, R. Houssin, F. Durant, J. Hénichart (2004)
New COX-2/5-LOX inhibitors: apoptosis-inducing agents potentially useful in prostate cancer chemotherapy.Journal of medicinal chemistry, 47 25
(1995)
Exploring QSAR: Hydro-phobic, electronic and steric constants
M. Pal, Venugopal Veeramaneni, Murali Nagabelli, Srinivas Kalleda, P. Misra, Seshagiri Casturi, Koteswar Yeleswarapu (2003)
Conformationally restricted 3,4-diarylfuranones (2,3a,4,5-tetrahydronaphthofuranones) as selective cyclooxygenase-2 inhibitors.Bioorganic & medicinal chemistry letters, 13 10
(1990)
Anti-inflammatory and
N. Chauret, J. Yergey, C. Brideau, Richard Friesen, Joseph Mancini, D. Riendeau, José Silva, A. Styhler, L. Trimble, D. Nicoll-Griffith (2001)
In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663).Bioorganic & medicinal chemistry letters, 11 8
D. Picot, P. Loll, R. Garavito (1994)
The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1Nature, 367
M. Reddy, M. Mallireddigari, Venkat Pallela, P. Venkatapuram, R. Boominathan, S. Bell, E. Reddy (2005)
Design, synthesis, and biological evaluation of (E)- and (Z)-styryl-2-acetoxyphenyl sulfides and sulfones as cyclooxygenase-2 inhibitors.Bioorganic & medicinal chemistry, 13 5
M. Uddin, P. Rao, E. Knaus (2005)
Design and synthesis of (Z)-1,2-diphenyl-1-(4-methanesulfonamidophenyl)alk-1-enes and (Z)-1-(4-azidophenyl)-1,2-diphenylalk-1-enes: novel inhibitors of cyclooxygenase-2 (COX-2) with anti-inflammatory and analgesic activity.Bioorganic & medicinal chemistry, 13 2
S. Prasanna, E. Manivannan, S. Chaturvedi (2004)
QSAR Analysis of Some Fused Pyrazoles as Selective Cyclooxygenase‐2 Inhibitors: A Hansch ApproachArchiv der Pharmazie, 337
M. Uddin, P. Rao, R. McDonald, E. Knaus (2005)
Design and synthesis of (E)-1,1,2-triarylethenes: novel inhibitors of the cyclooxygenase-2 (COX-2) isozyme.Bioorganic & medicinal chemistry letters, 15 2
F. Julémont, X. Leval, C. Michaux, J. Renard, J. Winum, J. Montero, J. Damas, J. Dogné, B. Pirotte (2004)
Design, synthesis, and pharmacological evaluation of pyridinic analogues of nimesulide as cyclooxygenase-2 selective inhibitors.Journal of medicinal chemistry, 47 27
R. Garg, A. Kurup, S. Mekapati, C. Hansch (2003)
Cyclooxygenase (COX) inhibitors: a comparative QSAR study.Chemical reviews, 103 3
S. Rich (2001)
The coxibs, selective inhibitors of cyclooxygenase-2.The New England journal of medicine, 345 23
K. Gans, W. Galbraith, Richard Roman, S. Haber, J. Kerr, W. Schmidt, C. Smith, W. Hewes, N. Ackerman (1990)
Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor.The Journal of pharmacology and experimental therapeutics, 254 1
T. Penning, J. Talley, S. Bertenshaw, J. Carter, P. Collins, S. Docter, M. Graneto, L. Lee, James Malecha, J. Miyashiro, R. Rogers, D. Rogier, S. Yu, G. Anderson, E. Burton, J. Cogburn, S. Gregory, C. Koboldt, W. Perkins, K. Seibert, A. Veenhuizen, Yan Zhang, P. Isakson (1997)
Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).Journal of medicinal chemistry, 40 9
A quantitative structure‐activity relationship (QSAR) analysis of 10 structurally diverse set of compounds recently reported as cyclooxygenase (COX) inhibitors has been performed using ClogP, CMR, aromatic substituent constants, and suitable indicator variables. These revealed several important physicochemical and structural requirements for COX‐1, COX‐2 inhibitory activity, and selective inhibition of COX‐2 versus COX‐1 among these novel ligands. Seventeen QSAR models reported herein provide interesting insights in understanding the hydrophobic, steric, electronic, and structural requirements of COX inhibition among these individual set of compounds. These results may be used to further the design and development of selective COX‐2 inhibitors among these newly reported COX inhibitors. Drug Dev Res 64:220–231, 2005. © 2005 Wiley‐Liss, Inc.
Drug Development Research – Wiley
Published: Apr 1, 2005
Keywords: QSAR; COX‐1; COX‐2; ClogP; CMR
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.